IPO market review: biotech leads a quiet week as Anthropic waits in the queue
The IPO market saw few listings, with biotech companies City Therapeutics (CTY) and Iambic Therapeutics (IAM) raising $200M and $150M respectively. CTY priced at $18.00, opened at $23.00, and saw a 28% debut increase. IAM priced at $16.00 and is currently trading at $23.87. Anthropic (ANTP) is expected to IPO soon, but investors may seek lower valuation. Fed rate hikes and macro caution may impact IPO activity.
How this was made
The 30-second read
Why it matters
For traders, the actionable elements are the newly priced listings (CTY, IAM, FLSC) and the sentiment read-through from CoreWeave’s drawdown, plus the near-term catalyst risk around Anthropic’s potential IPO timing and valuation debate.
Market read
This is a weekly IPO calendar and sentiment review, with tradable details for the named biotech listings and a pre-event watch item for Anthropic.
What to watch
Rate expectations are cited but not quantified; without details on IPO terms (lockups, warrants, redemption rights), post-listing direction may diverge from debut-day momentum.
Background
The piece reviews a thin IPO week, highlighting three biotech debuts and using CoreWeave’s post-IPO decline as a cautionary backdrop while Anthropic waits in the queue.
Ticker impact
City Therapeutics priced its IPO at $18 and opened at $23, with a 28% debut pop indicating strong demand and a new tradable listing.
Likely near-term support from oversubscription narrative, offset by typical post-IPO mean reversion risk.
The article cites midpoint pricing, a 28% first-day gain, and oversubscribed order allocation dynamics, which typically supports initial trading but does not eliminate fade risk.
Iambic Therapeutics priced at $16 to raise $150M and began trading Oct 15, with the stock now cited around $23.87.
Likely continued interest while momentum persists, but expect volatility as the market digests the offering and broader rate backdrop.
The piece provides a concrete IPO price, raise size, and current trading level, which can inform short-term positioning.
Frazier Life Sciences Acquisition II raised $75M in a small biotech-focused SPAC, creating a fresh capital-structure and trading catalyst.
Near-term trading likely driven by deal sentiment and liquidity, with direction uncertain without further terms.
The article confirms the raise and SPAC type but provides limited detail on structure, warrants, or redemption expectations.
CoreWeave is cited as down more than 60% from its post-IPO peak, with co-founders selling $3.3B since the March 2025 IPO.
Likely continued downside pressure or capped upside as investors price in post-IPO fade risk.
The article provides a specific drawdown magnitude and insider selling context, which can influence risk perception for the cohort.
Market effects
Biotech IPO demand is portrayed as strong while other sectors may wait, implying selective risk-on flows into life sciences platforms.
US IPO activity is framed alongside a Nasdaq drop over 1%, linking listing appetite to broader market risk.
AI IPO sentiment is influenced by Anthropic’s queue and CoreWeave’s post-IPO drawdown, which can spill into global AI-adjacent risk appetite.
Counterpoint
The strong biotech debut performance may reflect one-off deal quality and allocation mechanics, not a durable sector-wide bid.
Key entities
- companyCity Therapeutics
Biotech IPO priced at $18, opened at $23, up 28% on debut.
- companyIambic Therapeutics
Biotech IPO priced at $16 to raise $150M, trading around $23.87 after starting Oct 15.
- companyFrazier Life Sciences Acquisition II
Biotech-focused SPAC raised $75M.
- companyCoreWeave
AI infrastructure company cited as down over 60% from post-IPO peak; co-founders sold $3.3B since IPO.
- companyAnthropic
AI company listed on the IPO calendar for Oct 23, with valuation timing uncertainty and AI safety concerns.
